Oversubscribed round enables late-stage clinical development of lead candidate, a micro-RNA-132 inhibitor, in heart failure and further accelerates pipeline expansion
Munich, Germany, August 25, 2021 [...]
to advance clinical and commercial development of BRIMOCHOL™ for presbyopia
Amsterdam, The Netherlands, 10 August 2021 – LSP, one of the leading life sciences and health care investors, today ann [...]
Plan to initiate the IMAG1NE Phase 1/2 clinical study of TK-8001, a TCR-T cell therapy for MAGE-A1 positive solid tumors, in 2021
Munich, Germany – August 2, 2021 – LSP, one of the leading life [...]
Funding propels Artios’ ability to progress beyond synthetic lethality and to continue the exploitation of the full spectrum of oncology vulnerabilities presented by the DNA Damage Response through deployment of [...]
of Phase 1/2 EXACT Clinical Study of XC001 Gene Therapy for Refractory Angina
Independent Data Monitoring Committee authorized proceeding to Phase 2 at highest dose level tested following review of clin [...]
Proceeds dedicated to the development of novel small molecule therapeutics for neurodegenerative diseases
Innovative drug discovery platform leveraging insights from novel targets and pathways, resilience to [...]
to advance cancer diagnostic and drug discovery and development platform leveraging proprietary MicroOrganoSphere technology
Xilis’ MicroOrganoSphere™ (MOS) technology generates thousands of miniatu [...]
and Trunk Control in Spinal Cord Injury
Third Breakthrough Device Designation Awarded to the Company for Innovative Technologies
EINDHOVEN, Netherlands & LAUSANNE, Switzerland, June 17, 2021--(BU [...]
Proceeds dedicated to advance Herpes simplex treatment IM-250 to Phase II
IM-250 demonstrates unprecedented impact on viral reservoir in preclinical studies
Munich, Germany, June 9, 2021 - LSP, [...]
Oversubscribed round enables late-stage clinical development of lead candidate, a micro-RNA-132 inhibitor, in heart failure and further accelerates pipeline expansion
Munich, Germany, August 25, 2021 [...]
to advance clinical and commercial development of BRIMOCHOL™ for presbyopia
Amsterdam, The Netherlands, 10 August 2021 – LSP, one of the leading life sciences and health care investors, today ann [...]
Plan to initiate the IMAG1NE Phase 1/2 clinical study of TK-8001, a TCR-T cell therapy for MAGE-A1 positive solid tumors, in 2021
Munich, Germany – August 2, 2021 – LSP, one of the leading life [...]
Funding propels Artios’ ability to progress beyond synthetic lethality and to continue the exploitation of the full spectrum of oncology vulnerabilities presented by the DNA Damage Response through deployment of [...]
of Phase 1/2 EXACT Clinical Study of XC001 Gene Therapy for Refractory Angina
Independent Data Monitoring Committee authorized proceeding to Phase 2 at highest dose level tested following review of clin [...]
Proceeds dedicated to the development of novel small molecule therapeutics for neurodegenerative diseases
Innovative drug discovery platform leveraging insights from novel targets and pathways, resilience to [...]
to advance cancer diagnostic and drug discovery and development platform leveraging proprietary MicroOrganoSphere technology
Xilis’ MicroOrganoSphere™ (MOS) technology generates thousands of miniatu [...]
and Trunk Control in Spinal Cord Injury
Third Breakthrough Device Designation Awarded to the Company for Innovative Technologies
EINDHOVEN, Netherlands & LAUSANNE, Switzerland, June 17, 2021--(BU [...]
Proceeds dedicated to advance Herpes simplex treatment IM-250 to Phase II
IM-250 demonstrates unprecedented impact on viral reservoir in preclinical studies
Munich, Germany, June 9, 2021 - LSP, [...]
Follow us
